Photobiomodulation Technology in the Treatment of Alzheimer's Disease

Source: https://www.led-professional.com/all/photobiomodulation-technology-in-the-treatment-of-alzheimers-disease?utm_source=LED+professional+-+FREE+Information+Service&utm_campaign=aebba969c9-LEDprofessionalNewsletter%28LpN%29-APR1%2C2021&utm_medium=email&utm_te

Date: 17-05-2021

REGEnLIFE, a company specialized in the research and development of innovative photo-medical technologies for the prevention and treatment of neurodegenerative diseases, announces today the promising results of the pilot clinical trial evaluating its technology in Alzheimer’s disease (AD).

  • Within treated patient group, trends showed improved cognitive and executive functions, improved language comprehension and verbal memory, in comparison to placebo group
  • REGEnLIFE’s technology shown to be safe and well-tolerated by patients
  • Initial results open up new possibilities for development of brain-gut stimulation device for prevention and treatment of neurodegenerative diseases

REGEnLIFE, a company specialized in the research and development of innovative photo-medical technologies for the prevention and treatment of neurodegenerative diseases, announces today the promising results of the pilot clinical trial evaluating its technology in Alzheimer’s disease (AD). The results were presented by Professor Jacques Touchon, scientific advisor on the trial, at the 15th International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD 2021), held online from March 9 to 14, 2021.

READ MORE HERE

Go back